Haemonetics
HAE
#3835
Rank
C$5.04 B
Marketcap
C$111.02
Share price
1.78%
Change (1 day)
7.77%
Change (1 year)

P/E ratio for Haemonetics (HAE)

P/E ratio as of July 2026 (TTM): 38.7

According to Haemonetics's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 38.7015. At the end of 2025 the company had a P/E ratio of 21.9.

P/E ratio history for Haemonetics from 2001 to 2026

PE ratio at the end of each year

Year P/E ratio Change
202521.9-27.98%
202430.4-10.85%
202334.2-18.7%
202242.0-65.71%
2021123
2018112-165.46%
2017-171-234.9%
2016127-486.28%
2015-32.8-150.98%
201464.311.03%
201357.9

P/E ratio for similar companies or competitors

Company P/E ratio P/E ratio differencediff. Country
Johnson & Johnson
JNJ
30.0-22.43%๐Ÿ‡บ๐Ÿ‡ธ USA
Medtronic
MDT
22.2-42.66%๐Ÿ‡ฎ๐Ÿ‡ช Ireland
Thermo Fisher Scientific
TMO
30.8-20.29%๐Ÿ‡บ๐Ÿ‡ธ USA
Baxter
BAX
-10.5-127.24%๐Ÿ‡บ๐Ÿ‡ธ USA
Becton Dickinson
BDX
47.2 21.94%๐Ÿ‡บ๐Ÿ‡ธ USA
Stryker Corporation
SYK
37.7-2.61%๐Ÿ‡บ๐Ÿ‡ธ USA
PerkinElmer
PKI
15.0-61.33%๐Ÿ‡บ๐Ÿ‡ธ USA
Cerus Corporation
CERS
-58.4-250.90%๐Ÿ‡บ๐Ÿ‡ธ USA

How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.